His research group have particular interests in heart muscle and conditions that affect it such as cardiomyopathy, Fabry, amyloid, valve disease, cardio-oncology, athleticism and aging which he measures using developed techniques (LGE, T1 mapping, perfusion mapping). A major current work program is measuring the heart using developed AI that exceeds human performance. He has published more than 500 papers and works inpartnership with Pharma to develop surrogate endpoints for clincical trials including first in man studies. Another interest is in making scans faster/cheaper and inimproving/maintaining quality. He set up and led the international T1 mapping development group, mrimypacemaker and CMR for lower middle income countries.